Scienmag

FEBRUARY 4, 2022

million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, takes a promising step in the direction of developing […]. PHILADELPHIA — (Feb.

Vaccination 81

Vaccination Vaccine Development Research 81

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. MONDAY, Dec.

Scientist 52

Scientist Vaccination Vaccine Immune Response 52

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8)

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

Scienmag

DECEMBER 23, 2021

Credit: Julianna Han, Ward Lab at Scripps Research LA JOLLA, CA—Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine.

Vaccination 96

Vaccination Vaccine Research Antibody 96

Scienmag

JULY 19, 2022

Yale scientists have developed a novel Omicron-specific mRNA vaccine that offers superior immune protection against two viral subvariants than standard mRNA vaccines. The new vaccine, called Omnivax, increased neutralizing antibody response against the BA.1 New Haven, Conn. The […].

Vaccination 61

Vaccination Vaccine Development Antibody 61

Scienmag

DECEMBER 23, 2021

A team led by scientists at Weill Cornell Medicine, Scripps Research and the University of Chicago has identified an important site of vulnerability on influenza viruses—a site that future influenza vaccines and antibody therapies should be able to target to prevent or treat infections by a broad set of influenza strains.

Vaccination 67

Vaccination Vaccine Scientist Antibody 67

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. The company announced a phase 1 trial is beginning of its nasal spray vaccine just as scientists in the UK said they are considering a similar approach.

Vaccination 109

Vaccination Vaccine Immune Response Trials 109

Scienmag

MAY 12, 2021

Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)

Vaccination 47

Vaccination Vaccine Antibody Scientist 47

Scienmag

NOVEMBER 24, 2021

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective vaccines and therapies, as well as understand the long-term effects of the infection.

Vaccination 61

Vaccination Vaccine Antibody Scientist 61

pharmaphorum

JULY 27, 2021

Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year. The hope was that an inhaled antibody would reach higher levels in the lung, where it is most needed, than systemic antibodies.

Antibody 98

Antibody Clinical Development Scientist Development 98

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Medical Xpress

FEBRUARY 14, 2023

The immune system fights the coronavirus with antibodies and T cells. Scientists have a fairly good idea of how the virus avoids antibodies, including those promoted by vaccination, which is how variants of concern such as the omicron are known to appear.

Antibody 96

Antibody Scientist Vaccination Vaccine 96

The Pharma Data

FEBRUARY 12, 2022

The discovery, published in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping future coronavirus pandemics. In the new work, they mapped at atomic scale the site, or “epitope,” to which the antibody binds on the SARS-Cov-2 spike protein.

Scientist 52

Scientist Antibody Protein Vaccination 52

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccination 111

Vaccination Vaccine Immune Response Antibody 111

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

Drug Discovery World

MARCH 24, 2023

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

Vaccination 52

Vaccination Vaccine Development Genetics 52

Drug Discovery World

OCTOBER 3, 2023

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.

Vaccination 59

Vaccination Vaccine Clinical Trials Clinical Trials 59

Scienmag

AUGUST 17, 2020

. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use.

Antibody 50

Antibody Scientist Vaccination Vaccine 50

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

The Pharma Data

JANUARY 27, 2021

A new study has found that Eli Lilly and Regeneron may need to adjust their monoclonal antibody treatments to effectively fight fast-spreading COVID-19 variants, especially the South African mutation, which along with a UK variant has raised concerns among scientists that SARS-CoV-2 may mutate to resist vaccines and treatments.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Medical Xpress

JANUARY 24, 2023

Scientists have found the "booster" COVID-19 vaccine program led to a large boost in the antibodies that help protect against coronavirus. High levels of antibodies is associated with lower risk of severe infection.

Antibody 71

Antibody Scientist Vaccination Vaccine 71

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

pharmaphorum

FEBRUARY 19, 2021

Two researchers have suggested that the second dose of Pfizer and BioNTech’s COVID-19 vaccine could be delayed, as this would increase the number of people that can be protected while supplies are limited without compromising its efficacy. . Feature image copyright BioNTech SE 2020, all rights reserved.

Scientist 72

Scientist Vaccination Vaccine Antibody 72

STAT News

OCTOBER 19, 2022

… Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1 1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months , Reuters notes. Omicron-tailored 5 targeted vaccine later this year. 5 subvariants of Omicron.

Immune Response 98

Immune Response Scientist Vaccination Vaccine 98

Medical Xpress

NOVEMBER 10, 2022

Since the COVID-19 pandemic began almost three years ago, scientists have learned that an initial infection can lead to short- and long-term health risks affecting nearly every organ system in the body.

Antibody 102

Antibody Scientist Vaccination Vaccine 102

pharmaphorum

SEPTEMBER 8, 2022

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic infection.

Vaccination 72

Vaccination Vaccine Immune Response Antibody 72

Drug Discovery World

AUGUST 15, 2022

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial. . The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). Kenya, where malaria is endemic. . Official comments .

Trials 52

Trials Vaccination Vaccine Clinical Trials 52

Scienmag

JANUARY 25, 2021

OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.

Antibody 40

Antibody Scientist Vaccination Vaccine 40

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community. References.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

SEPTEMBER 14, 2020

Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. What are monoclonal antibodies?

Antibody 52

Antibody Trials Immune Response Vaccination 52

Sciensano

JULY 5, 2023

Vaccin COVID-19 Event type: symposium Audience: general public health professionals journalist PhD students policy makers scientists Description: Sciensano is pleased to invite you to its BelCoVac symposium, which will focus on studies on the COVID vaccine in Belgium.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52